PortalPublikationenCurrent resultson PSA-based prostate cancer detection

Current resultson PSA-based prostate cancer detection

Standard

Current resultson PSA-based prostate cancer detection. / Graefen, M; Schlomm, T; Steuber, T; Sauter, G.

in: BUNDESGESUNDHEITSBLA, Jahrgang 57, Nr. 3, 01.03.2014, S. 312-7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Graefen, M, Schlomm, T, Steuber, T & Sauter, G 2014, 'Current resultson PSA-based prostate cancer detection', BUNDESGESUNDHEITSBLA, Jg. 57, Nr. 3, S. 312-7. https://doi.org/10.1007/s00103-013-1905-0

APA

Graefen, M., Schlomm, T., Steuber, T., & Sauter, G. (2014). Current resultson PSA-based prostate cancer detection. BUNDESGESUNDHEITSBLA, 57(3), 312-7. https://doi.org/10.1007/s00103-013-1905-0

Vancouver

Graefen M, Schlomm T, Steuber T, Sauter G. Current resultson PSA-based prostate cancer detection. BUNDESGESUNDHEITSBLA. 2014 Mär 1;57(3):312-7. https://doi.org/10.1007/s00103-013-1905-0

Bibtex

@article{bcaacc0d059a4ea5991c85abcdc7810a,
title = "Current resultson PSA-based prostate cancer detection",
abstract = "Prostate cancer is the most common cancer and the third leading cause of cancer-specific death in men in Western industrialized countries. Implementation of the prostate-specific antigen (PSA) blood test as an early detection tool has led to a significant reduction of prostate cancer mortality in the USA. Apart from an earlier detection of clinically relevant tumors, regular PSA testing increases the risk of over-detection and over-treatment of clinically indolent tumors. In our view, a reliable stratification of indolent tumors in active surveillance programs is the key in avoiding or reducing overtreatment of early diagnosed prostate cancers. Along with better risk stratification, the expansion of PSA screening should be discussed in order to reduce the still high numbers of palliative treatments, metastases, and prostate cancer-related deaths.",
keywords = "Diagnostic Errors, Early Detection of Cancer, Evidence-Based Medicine, Humans, Male, Prevalence, Prostate-Specific Antigen, Prostatic Neoplasms, Reproducibility of Results, Risk Assessment, Sensitivity and Specificity, Tumor Markers, Biological",
author = "M Graefen and T Schlomm and T Steuber and G Sauter",
year = "2014",
month = mar,
day = "1",
doi = "10.1007/s00103-013-1905-0",
language = "Deutsch",
volume = "57",
pages = "312--7",
journal = "BUNDESGESUNDHEITSBLA",
issn = "1436-9990",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Current resultson PSA-based prostate cancer detection

AU - Graefen, M

AU - Schlomm, T

AU - Steuber, T

AU - Sauter, G

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Prostate cancer is the most common cancer and the third leading cause of cancer-specific death in men in Western industrialized countries. Implementation of the prostate-specific antigen (PSA) blood test as an early detection tool has led to a significant reduction of prostate cancer mortality in the USA. Apart from an earlier detection of clinically relevant tumors, regular PSA testing increases the risk of over-detection and over-treatment of clinically indolent tumors. In our view, a reliable stratification of indolent tumors in active surveillance programs is the key in avoiding or reducing overtreatment of early diagnosed prostate cancers. Along with better risk stratification, the expansion of PSA screening should be discussed in order to reduce the still high numbers of palliative treatments, metastases, and prostate cancer-related deaths.

AB - Prostate cancer is the most common cancer and the third leading cause of cancer-specific death in men in Western industrialized countries. Implementation of the prostate-specific antigen (PSA) blood test as an early detection tool has led to a significant reduction of prostate cancer mortality in the USA. Apart from an earlier detection of clinically relevant tumors, regular PSA testing increases the risk of over-detection and over-treatment of clinically indolent tumors. In our view, a reliable stratification of indolent tumors in active surveillance programs is the key in avoiding or reducing overtreatment of early diagnosed prostate cancers. Along with better risk stratification, the expansion of PSA screening should be discussed in order to reduce the still high numbers of palliative treatments, metastases, and prostate cancer-related deaths.

KW - Diagnostic Errors

KW - Early Detection of Cancer

KW - Evidence-Based Medicine

KW - Humans

KW - Male

KW - Prevalence

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

KW - Reproducibility of Results

KW - Risk Assessment

KW - Sensitivity and Specificity

KW - Tumor Markers, Biological

U2 - 10.1007/s00103-013-1905-0

DO - 10.1007/s00103-013-1905-0

M3 - SCORING: Zeitschriftenaufsatz

C2 - 24562706

VL - 57

SP - 312

EP - 317

JO - BUNDESGESUNDHEITSBLA

JF - BUNDESGESUNDHEITSBLA

SN - 1436-9990

IS - 3

ER -